The treatment of schizophrenic psychoses with gamma-type endorphins

Biol Psychiatry. 1982 Jan;17(1):83-98.

Abstract

The pharmacological actions of gamma-type endorphins show similarities to those of the neuroleptics. Two fragments of gamma-endorphin (beta-LPH 61-77) were therefore tested in patients with schizophrenic and schizo-affective psychoses who had shown an insufficient response to neuroleptics. The fragments were DT gamma E (beta-LPH 62-77) and DE gamma E (beta-LPH 66-77). Some of the patients studied responded favorably to this treatment. A number of criteria of differentiation between responders and nonresponders are discussed. The influence of DT gamma E on the central DA metabolism differs from that of the neuroleptics. It is therefore conceivable that gamma-type endorphins represent a different principle of action. The therapeutic efficacy of these compounds lends support to the hypothesis that disorders of central endorphin metabolism may play a role in the pathogenesis of psychoses of the schizophrenic type.

Publication types

  • Clinical Trial

MeSH terms

  • Brain / drug effects
  • Clinical Trials as Topic
  • Dopamine / metabolism
  • Double-Blind Method
  • Endorphins / therapeutic use*
  • Humans
  • Peptide Fragments / therapeutic use*
  • Psychotic Disorders / drug therapy
  • Receptors, Dopamine / drug effects
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology
  • beta-Endorphin*
  • gamma-Endorphin

Substances

  • Endorphins
  • Peptide Fragments
  • Receptors, Dopamine
  • beta-Endorphin
  • gamma-Endorphin
  • gamma-endorphin, des-Tyr(1)-
  • des-enkephalin-gamma-endorphin
  • Dopamine